Grace Therapeutics, Inc. GRCE
Set alert
1.94 USD 0.00 0.00%
At close · Oct 30
1.94 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.87 Day range 1.98
1.81 52-week range 5.13
- YTD
- -43.93%
- 1 year
- -39.18%
- Open
- 1.95
- Prev close
- 1.94
- Mkt cap
- 40.81M
- Vol
- 85.94K
- Avg vol
- 139.87K
- EPS
- -1.17
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.87
- High
- 1.98
- Forward P/E
- -2.90
- Beta
- 1.51
- Short ratio
- 3.25
- Inst. own
- 21.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 10, 2025
- 50-d avg
- 3.44
- 200-d avg
- 3.04
- 1y target
- 10.44
2Y chart
Events in this range
- Nov 13, 2024Earnings: -0.33; estimate -0.33; surprise 0%
- Feb 10, 2025Earnings: —; estimate -0.27; surprise —%
Signals (84)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| RSI: Oversold | Jul 29, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | May 12, 2026 | 5 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| RSI: Oversold | Apr 23, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Apr 7, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 6, 2026 | 6 months ago |
| RSI: Overbought | Apr 2, 2026 | 7 months ago |
| RSI: Overbought | Mar 25, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 4, 2026 | 8 months ago |
| RSI: Overbought | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 17, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 23, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 14, 2026 | 9 months ago |
| RSI: Overbought | Jan 7, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 2, 2026 | 10 months ago |
| RSI: Overbought | Jan 2, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Nov 18, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 14, 2025 | 11 months ago |
| SMA: Bullish | Nov 13, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 14, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 9, 2025 | 1 year ago |
| SMA: Bearish | Oct 2, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 17, 2025 | 1 year ago |
| SMA: Bullish | Sep 16, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 15, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 9, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| SMA: Bearish | Aug 27, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 27, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| SMA: Bullish | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 24, 2025 | 1 year ago |
| RSI: Overbought | Jul 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| MACD: Sell Signal | May 28, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| MACD: Sell Signal | May 15, 2025 | 1 year ago |
| RSI: Overbought | May 7, 2025 | 1 year ago |
| RSI: Overbought | May 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 4, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 20, 2025 | 1 year ago |
| RSI: Oversold | Mar 11, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| SMA: Bearish | Jan 28, 2025 | 1 year ago |
| SMA: Bullish | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 7, 2025 | 1 year ago |
| RSI: Overbought | Dec 4, 2024 | 1 year ago |
Key statistics
- Market cap
- 37.11M
- Enterprise value
- 14.15M
- Trailing P/E
- 0.00
- Forward P/E
- -2.90
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.56
- EPS (TTM)
- -1.29
- Beta
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.58M
- Total cash
- 19.41M
- Total debt
- 0
- Return on equity
- -18.56%
- Shares outstanding
- 10.14M
- Short % of float
- 1.60%
- 50-day average
- 3.44
- 200-day average
- 3.04
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.44 +438.4% upside
Now 1.94
- Target (low)
- 7.79
- Target (mean)
- 10.44
- Target (high)
- 12.30
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 10, 2025
Expected Feb 10, 2025. Consensus EPS estimate -0.45333.
Financials — quick view
GRCE Revenue — quarterly 0
GRCE Net income — quarterly -15.79M
GRCE EPS — quarterly -0.91
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | -0.27 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -0.33 | -0.33 | 0.00 | 0.00% |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acastipharma.com
News
- Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
- Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate
- Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
- Grace Therapeutics Announces $10 Million Private Placement
- Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
- Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
- Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate
- Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Your note
Sign in to keep a note on GRCE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 9.46% | 959,571 | 3.51M | Sep 29, 2024 |
| AIGH Capital Management LLC | 6.32% | 641,083 | 2.35M | Sep 29, 2024 |
| Bank of America Corporation | 4.88% | 494,698 | 1.81M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.16% | 16,147 | 59.10K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.03% | 2,719 | 9.95K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 2,732 | 10.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,058 | 11.19K | Oct 30, 2024 |